COMPASS Pathways Plc - American Depository Shares (CMPS)

$10.49 0.11 (1.06%)

14:59 EST CMPS Stock Quote Delayed 30 Minutes

Compass Pathways (CMPS): The McDonald’s of Psychedelics?

By Luke Lango, InvestorPlace Senior Investment Analyst Sep 6, 2022

This week, we’re talking about my Big Three investing themes for the rest of the year (and beyond), which includes a psychedelic stock favorite, Compass Pathways (CMPS).

7 Psychedelics Stocks to Buy for a Big Drug Boom

3 Best Psychedelic Stocks to Buy Now

Dear Psychedelic Stocks Fans, Watch This Key Catalyst

Volume:

Previous Close -

Market Cap -

PE Ratio -

EPS -

Volume (Avg. Vol.) 153,724

Day's Range $10.10 - $10.54

52-Week Range $6.54 - $21.50

Dividend & Yield N/A (N/A)

CMPS Stock Predictions, Articles, and COMPASS Pathways Plc - American Depository Shares News

From InvestorPlace
From the Web

Growing Psychedelic Interest Will Help Push Compass Pathways Stock Up 3X By 2022

By Luke Lango and the InvestorPlace Research Staff Aug 4, 2021

By 2030, psychedelic therapy will be the gold standard for mental health treatment. And Compass is at the forefront of commercialization.

7 Stocks to Buy if You Think Alternative Therapies Are the Future

By Josh Enomoto, InvestorPlace Contributor Aug 2, 2021

Here are seven stocks to buy if you're optimistic about the potential for alternative therapies to become mainstream treatments.

What Will the Stock Market Do Today? 3 Big Stories to Watch.

By Sarah Smith, Editor-in-Chief, InvestorPlace.com Jul 2, 2021

So what will the stock market do today? All eyes are on Richard Branson as the space race between him and Jeff Bezos heats up.

3 Psychedelics Stocks Getting High Thanks to the Newly Launched PSY ETF

By Muslim Farooque, InvestorPlace Contributor Jun 15, 2021

These psychedelic stocks have compelling product pipelines and have built up a great head of steam in the past month thanks to the PSY ETF.

Compass Pathways Offers Chance on Exploratory Mental Health Treatments

By David Moadel, InvestorPlace Contributor May 18, 2021

Over the past year, CMPS stock has been going nowhere fast. However, there's been recent progress in advancing psilocybin-assisted therapy.

What Did the Stock Market Do Today? 3 Big Stories to Catch Up On.

By Sarah Smith, Editor-in-Chief, InvestorPlace.com May 17, 2021

So what did the stock market do today? All eyes were on Bitcoin prices, EV stocks and hype in the psychedelics market.

3 Top Psychedelic Stocks to Own Now

By Ian Cooper May 6, 2021

Psychedelics could be a game-changer for millions struggling with mental health. Here are some of the top ways to trade psychedelic stocks.

MNMD Stock: A MindMed Buzz Kill as the Psychedelic Shares Tank on First Day of Trading

By William White, InvestorPlace Writer Apr 27, 2021

MindMed (MNMD) stock isn't doing so hot with shares taking a beating on the first day of trading at their new home on the Nasdaq.

What Did the Stock Market Do Today? 3 Big Stories to Catch Up On.

By Sarah Smith, Editor-in-Chief, InvestorPlace.com Apr 26, 2021

So what did the stock market do today? All eyes were on Tesla stock as it set a new record and MNMD stock ahead of its listing.

The Shroom Boom Is Here. Buy CMPS Stock to Ride This Explosive Megatrend.

By Luke Lango, InvestorPlace Senior Investment Analyst Apr 26, 2021

IPOs. Uplistings. Academic studies. All the stars are aligning for "shroom stocks", so it's time to buy CMPS stock on the dip.

3 of the Top Psychedelic Stocks That Will Blow Your Mind

By Muslim Farooque, InvestorPlace Contributor Apr 20, 2021

These psychedelic stocks are the sector's needle-movers and have the potential to make a big splash this year

7 Healthcare Stocks to Buy and Hold for the Long Term

By Faisal Humayun, InvestorPlace Contributor Mar 12, 2021

These steady, strong healthcare stocks are great picks for investors to buy and hold onto for at least the next five years.

5 Groovy Psychedelic Stocks to Buy

By Ian Cooper Jan 8, 2021

Psychedelic stocks could have another “far out” year ahead with U.S. FDA support, as well as more clinical trials that are under way.

3 Psychedelic Stocks Taking Mental Health Seriously

By Faisal Humayun, InvestorPlace Contributor Dec 30, 2020

These psychedelic stocks are worth accumulating on corrections. The companies are holding clinical trials for mental health drugs.

Find Your Next 10X Winner in the Burgeoning Shroom Boom

By Luke Lango, InvestorPlace Senior Investment Analyst Dec 3, 2020

Psychedelic stocks are going to surge as the once "hardcore" group of pschedelic drugs gains widespread mainstream medicinal acceptance.

4 Megatrends the Election Has Kicked Into Hyperdrive

By Luke Lango, InvestorPlace Senior Investment Analyst Dec 3, 2020

These four megatrends are in high gear after the 2020 Presidential election. These are the best stocks to buy now.

Trade the Burgeoning ‘Shroom Boom’ with COMPASS Pathways Stock

By David Moadel, InvestorPlace Contributor Nov 12, 2020

Could psilocybin therapy become a hyper-growth market in mental health medicine? It could happen, so consider a position in CMPS stock.

Thanks to the Shroom Boom, This Small Stock Could Soar

By Luke Lango, InvestorPlace Senior Investment Analyst Oct 13, 2020

In mid-September, the true leader of the Shroom Boom -- COMPASS Pathways (NASDAQ:CMPS) -- finally came public via an IPO that was a huge success.

Compass Pathways IPO: 5 Things for Potential CMPS Investors to Know

By Sarah Smith, Editor-in-Chief, InvestorPlace.com Sep 21, 2020

CMPS stock shot up more than 70% during its first trading. Here is what else investors need to know about the recent Compass Pathways IPO.

H.C. Wainwright Reaffirms Their Buy Rating on COMPASS Pathways (CMPS)

From TipRanks Dec 9, 2022

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on COMPASS Pathways (CMPS – Research Report), with a pric...

Analysts Offer Insights on Healthcare Companies: Cooper Co (COO), COMPASS Pathways (CMPS) and Kronos Bio (KRON)

From TipRanks Dec 9, 2022

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cooper Co (COO – Research Report), COMPASS Pathways (CMPS – Resea...

Compass psilocybin therapy shows promise in depression, bipolar disorder in trials

From Seeking Alpha Dec 8, 2022

Compass Pathways (CMPS) said new positive data demonstrating the potential of COMP360 psilocybin therapy in depression were presented at the Annual Meeting of the American College...

Analysts Say These 2 Stocks Could Double Your Money — Here’s Why They Could Jump

From TipRanks Dec 1, 2022

We’re getting near an inflection point in the markets, and change is in the air. In the immediate short-term, the Fed is expected to slow down on its rate-hike poli...

3 Big Trends Shaking Up Psychedelic Stocks

From The Motley Fool Nov 29, 2022

Major positive shifts are happening, but the field faces new headwinds too.

COMPASS Pathways (CMPS) Receives a New Rating from Berenberg Bank

From TipRanks Nov 21, 2022

Berenberg Bank analyst Caroline Palomeque initiated coverage with a Buy rating on COMPASS Pathways (CMPS – Research Report) today and set a price target of $3...

COMPASS Pathways Plc - American Depository Shares (CMPS)

Compass Pathways (CMPS): The McDonald’s of Psychedelics?

7 Psychedelics Stocks to Buy for a Big Drug Boom

3 Best Psychedelic Stocks to Buy Now

Dear Psychedelic Stocks Fans, Watch This Key Catalyst

11 Best Stocks to Buy for 2023

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

COMPASS Pathways Plc - American Depository Shares (CMPS)

11 Best Stocks to Buy for 2023

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

CMPS Stock Predictions, Articles, and COMPASS Pathways Plc - American Depository Shares News

Subscriber Sign in